Comparing recombinant human rabies monoclonal antibody (ormutivimab) with human rabies immunoglobulin (HRIG) for postexposure prophylaxis: A phase III, randomized, double-blind, non-inferiority trial

Comparing recombinant human rabies monoclonal antibody (ormutivimab) with human rabies immunoglobulin (HRIG) for postexposure prophylaxis: A phase III, randomized, double-blind, non-inferiority trial

Objectives: To evaluate the immunogenicity and safety of an anti-rabies monoclonal antibody (mAb), ormutivimab, compared with human rabies immunoglobulin (HRIG). Methods: This phase III trial was designed as a randomized, double-blind, non-inferiority clinical trial in patients aged ≥18 years with s...

Full description

Bibliographic Details
Main Authors: Xiaoqiang Liu, Yufeng Li, Jingyu Li, Jianmei Zhou, Jiangshu Guo, Yi Pu, Ya Jiang, Yaling Zhou, Zhiwei Jiang, Qun Shu, Cha Wang, Jingke Wang, Yu Zhao, Wei Zhao, Hui Wang, Jingshuang Wei, Hancheng Yu, Jian Gao, Xiaona Li
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:International Journal of Infectious Diseases
Subjects:
Rabies
Postexposure prophylaxis
Monoclonal antibody
Rabies passive immune preparation
Rabies immunoglobulin
Rabies vaccine
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971223005696

Internet

http://www.sciencedirect.com/science/article/pii/S1201971223005696

Similar Items